Loading
A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease is a phase 3 interventional study registered as NCT00434148 by Novartis Pharmaceuticals, with 162 participants recorded, started 2006-12 and reaching its primary completion in 2010-03. Interventions recorded: Pasireotide. Conditions recorded: Cushing's Disease.
Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
162 enrolled.
95% CI 7.0 to 22.3; Figures from the ClinicalTrials.gov results section (first posted 2013-02-06), not from a publication · 95% CI 16.6 to 35.9
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Groupprimary | Pasireotide 600 ug | 82 | 12 participants | - | - | link |
| Pasireotide 900 ug | 80 | 21 participants |
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.